secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2026-08-06T11:06:30+00:00
Accession:  0001193125-26-336700
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Therapeutics Q2 2026 net loss $53.7M; cash $356M; pipeline on track
----------------------------------------------------------------------------

- Net loss $53.7M vs $70.1M YoY; R&D expenses $44.4M vs $61.0M; G&A $12.8M vs $14.8M.
- Cash and investments $356M as of June 30, 2026; runway into 2029.
- CLN-049 Phase 2 in R/R AML to start Q3 2026 after positive FDA End-of-Phase 1 meeting.
- CLN-978 multi-dose data in RA Q3 2026, SLE Q4 2026; Phase 2 expansion early 2027.
- Zipalertinib NDA accepted; PDUFA Feb 27, 2027; Cullinan eligible for $30M on 2L approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312526336700/0001193125-26-336700-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312526336700/cgem-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-336700

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer